| 1 |
WHO. Global hepatitis report, 2017[EB/OL]. (2019-11-06)[2021-03-31].
URL
|
| 2 |
王贵强，王福生，庄辉，等. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志，2019, 35(12)：2648-2669.
|
| 3 |
Pfitzmann R, Nussler NC, Hippler-Benscheidt M, et al. Long-term results after liver transplantation[J]. Transpl Int, 2008, 21(3)：234-246.
|
| 4 |
Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease[J]. Hepatology, 1991, 13(4)：619-626.
|
| 5 |
O′Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications[J]. J Hepatol, 1992, 14(1)：104-111.
|
| 6 |
Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: What have we learned from our results？[J]. Hepatology, 1991, 13(4)：796-799.
|
| 7 |
Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1)：261-283.
|
| 8 |
Lok AS, McMahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis[J]. Hepatology, 2016, 63(1)：284-306.
|
| 9 |
Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy[J]. J Hepatol, 2012, 57(2)：442-450.
|
| 10 |
Singal AK, Fontana RJ. Meta-analysis：oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis[J]. Aliment Pharmacol Ther, 2012, 35(6)：674-689.
|
| 11 |
Boglione L, D′Avolio A, Cariti G, et al. Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia[J]. J Clin Virol, 2013, 56(2)：167-169.
|
| 12 |
Mazzaro C, Dal Maso L, Urraro T, et al. Hepatitis B virus related cryoglobulinemic vasculitis：A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC[J]. Dig Liver Dis, 2016, 48(7)：780-784.
|
| 13 |
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4)：1560-1599.
|
| 14 |
Jimenez-Perez M, Gonzalez-Grande R, Mostazo Torres J, et al. Management of hepatitis B virus infection after liver transplantation[J]. World J Gastroenterol, 2015, 21(42)：12083-12090.
|
| 15 |
Westin J, Aleman S, Castedal M, et al. Management of hepatitis B virus infection, updated Swedish guidelines[J]. Infect Dis (Lond), 2020, 52(1)：1-22.
|
| 16 |
De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections[J]. Clin Microbiol Rev, 2003, 16(4)：569-596.
|
| 17 |
Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J]. Gastroenterology, 2011，140(1)：132-143.
|
| 18 |
Giesler KE, Liotta DC. Next-generation reduction sensitive lipid conjugates of tenofovir: Antiviral activity and mechanism of release[J]. J Med Chem, 2016, 59(22)：10244-10252.
|
| 19 |
任天棋，杨倩倩，马鹤铭，等. TAF治疗慢性乙型肝炎的研究进展[J]. 肝脏，2019, 24(11)：1319-1322.
|
| 20 |
Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection：a randomised，double-blind, phase 3，non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3)：196-206.
|
| 21 |
Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy[J]. Antimicrob Agents Chemother, 2015, 59(6)：3563-3569.
|
| 22 |
Cholongitas E, Tziomalos K, Pipili C. Management of patients with hepatitis B in special populations[J]. World J Gastroenterol, 2015, 21(6)：1738-1748.
|
| 23 |
Tanaka T, Renner EL, Selzner N, et al. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation[J]. Can J Gastroenterol Hepatol, 2014, 28(1)：41-44.
|
| 24 |
Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: A systematic review[J]. Am J Transplant, 2013, 13(2)：353-362.
|
| 25 |
Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence[J]. Transpl Int, 2014, 27(10)：1022-1028.
|
| 26 |
Manini MA, Whitehouse G, Bruce M, et al. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal[J]. Dig Liver Dis, 2018, 50(9)：944-953.
|
| 27 |
Rashidi-Alavijeh J, Straub K, Achterfeld A, et al. Safety and efficacy of tenofovir alafenamide in liver transplant recipients：A single center experience[J]. Transpl Infect Dis, 2020：e13522.
|
| 28 |
Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection：a randomised，double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3)：185-195.
|
| 29 |
Saab S, Song D, Challita YP, et al. Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B[J]. Clin transplant, 2019：e13740.
|
| 30 |
Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2012, 35(11)：1317-1325.
|
| 31 |
Wong GL, Tse YK, Wong VW, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53，500 subjects[J]. Hepatology, 2015, 62(3)：684-693.
|
| 32 |
Lee D, Yun BC, Seo KI, et al. Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate[J]. Medicine, 2019, 98(50)：e18351.
|
| 33 |
Vasudevan A, Ardalan ZS, Ahmed N, et al. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation[J]. JGH Open, 2018, 2(6)：288-294.
|
| 34 |
Wong GL, Seto WK, Wong VW, et al. Review article：long-term safety of oral anti-viral treatment for chronic hepatitis B[J]. Aliment Pharmacol Ther, 2018, 47(6)：730-737.
|
| 35 |
Sripongpun P, Mannalithara A, Kwo PY, et al. Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 747-749.
|
| 36 |
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2)：370-398.
|
| 37 |
European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1)：167-185.
|
| 38 |
Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults[J]. HIV Med, 2008, 9(2)：82-88.
|
| 39 |
Yang JX, Liu BM, Li XG, et al. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients[J]. Antivir Ther, 2010, 15(8)：1171-1178.
|
| 40 |
Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations[J]. J Hepatol, 2008, 48(3)：391-398.
|
| 41 |
Jiang D, Wang J, Zhao X, et al. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance[J]. Liver Int, 2020, 40(1)：83-91.
|
| 42 |
Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(6)：1093-1102.
|
| 43 |
Cathcart AL, Chan HL, Bhardwaj N, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection[J]. Antimicrob Agents Chemother, 2018, 62(10)：e01064-18.
|
| 44 |
Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy[J]. Hepatology, 2000, 31(6)：1318-1326.
|
| 45 |
Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif[J]. Antimicrob Agents Chemother, 2006, 50(11)：3867-5874.
|
| 46 |
Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure[J]. J Antimicrob Chemother, 2008, 48(5)：747-755.
|